Study Evaluating the Efficacy and Safety of Simvastatin Alone Compared With Simvastatin Plus Ezetimibe in Type 2 Diabetic Patients (0653-021)(COMPLETED)

NCT00551876 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

214

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: MK0653, ezetimibe / Duration of Treatment: 30 Weeks
DRUG: Comparator : ezetimibe (+) simvastatin / Duration of Treatment: 30 Weeks

Sponsor

Organon and Co